Madrigal Pharmaceuticals, Inc. research snapshot
MDGL AI stock analysis currently reads Madrigal Pharmaceuticals, Inc. as a commercial-stage MASH specialist whose value is concentrated in Rezdiffra (resmetirom), the first approved therapy for MASH with moderate to advanced fibrosis. At the July 12, 2026 data cutoff, MDGL traded near $536.70 with an implied market capitalization of about $12.38 billion using 23.06 million shares. FY2025 net sales reached $958.4 million, Q1 2026 net sales reached $311.3 million, and the company still reported net losses while holding $817.9 million in cash and securities as of March 31, 2026. This page uses scenarios, technical levels, and source-backed facts. It is informational research, not investment advice.
Current price
$536.70
Market cap
$12.38 billion
AI score
62 / 100
Rating
High-growth MASH launch, single-product and competition risk
Trend status
Commercial growth strong, technical uptrend intact, profitability still incomplete
Data cutoff (updated weekly)
July 12, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Madrigal sells Rezdiffra, an oral thyroid hormone receptor-beta agonist for MASH with fibrosis, turning specialist diagnosis and prescribing into product revenue with high gross margins typical of specialty pharma. | High |
| Moat | First approved MASH-specific medicine, clinical evidence, specialist relationships, and EU expansion support the moat, but GLP-1 MASH competition and future pipeline entrants can narrow it. | Medium |
| Management | CEO Bill Sibold and the commercial team have executed a rapid Rezdiffra launch, expanded patient counts, and added pipeline optionality such as an oral GLP-1 license, while still funding losses. | Medium-high |
| Financial trend | FY2025 revenue rose to $958.4 million from $180.1 million in 2024, Q1 2026 revenue reached $311.3 million up 127% year over year, and FY2025 net loss was $288.3 million with Q1 2026 net loss of $94.4 million. | High |
| Valuation | At $536.70, MDGL traded near 10.9x TTM revenue and about 12.9x FY2025 sales, with a negative PE near -41.8x on trailing losses, so valuation depends on continued growth and a path to profits. | Medium-high |
| Technical trend | ChartMill showed short-term and long-term trends up, price above SMA 20, 50, and 200, support near $510 to $518, and a 52-week range of $286.44 to $615. | Medium-high |
| Risk level | Main risks are Rezdiffra concentration, Novo Nordisk and other MASH competitors, payer access and net price pressure, ongoing operating losses, and clinical or label setbacks. | Medium-high |
| AI confidence | High for descriptive research and calculations. Lower for exact price outcomes because biotech and specialty-pharma stocks reprice around competition, reimbursement, and quarterly demand data. | High data confidence |
| Investment certainty | Medium-low certainty. MDGL has a valuable commercial franchise in MASH, but the setup is less certain once competition, profitability timing, and premium sales multiples are included. | Medium-low |
MDGL AI stock forecast
The MDGL AI stock forecast uses scenario math around the $536.70 quote. Because MDGL is still loss-making on a GAAP basis, the audited three-year framework applies an assumed path-to-profitability EPS proxy of $6.00 with bullish, base, and bearish growth and PE assumptions. That framework produced a bullish area near $938, a base area near $328, and a bearish area near $111 before dilution, competition shocks, or major reimbursement changes.
$900 to $960
More likely if Rezdiffra keeps adding patients in the U.S. and Europe, combination or pipeline programs de-risk multi-year growth, net pricing holds, and investors keep paying a premium growth multiple as profitability approaches.
$310 to $340
More likely if sales keep rising but growth decelerates, GLP-1 MASH competition and discounting compress multiples, and the market values MDGL closer to a maturing single-product specialty company.
$100 to $120
More likely if patient growth stalls, competition or payer pressure cuts net revenue, losses persist longer than expected, dilution rises, or the stock rerates toward a low earnings multiple on weaker fundamentals.
MDGL AI technical analysis
MDGL AI technical analysis is constructive as of the July 12, 2026 cutoff. ChartMill closed MDGL at $536.70 with a 10/10 technical rating and 4/10 setup score, short-term and long-term trends up, RSI near 55.75, and support zones around $510 to $518, then $496 and $481. No resistance zones were flagged because price was trading in the upper part of the recent range, while the 52-week band ran from $286.44 to $615.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $536.70 | ChartMill close used with Yahoo and CNN market-cap references for July 2026 research and market cap math. |
| Near support | $510 to $518 | ChartMill listed a support zone from $510.31 to $518.39 formed by multiple trend lines and moving averages. |
| Secondary support | $496, then $481 | ChartMill listed weekly support near $496.28 and $480.76 if the primary zone fails. |
| Moving averages | Price above SMA 20, 50, and 200 | ChartMill showed SMA 20 near $518.39, SMA 50 near $511.48, SMA 100 near $495.63, and SMA 200 near $499.95, all below the recent close. |
| Resistance | Recent highs near $569 to $615 | No formal resistance zones were detected by ChartMill. Practical upside references include the 10-day high near $569.44 and the 52-week high near $615. |
| Momentum | Uptrend with neutral RSI | RSI 14 near 55.75 and MACD above zero support a constructive trend without extreme overbought readings on the daily snapshot. |
| Volume | Event-sensitive biotech volume | Average volume around 345k shares. Compare spikes with earnings, payer news, competitor MASH labels, and EU launch updates. |
| Volatility | Medium-high for a commercial biotech | ChartMill ATR was about 4.1%. Expect larger moves around quarterly patient metrics, net price, competition headlines, and cash-burn updates. |
| Invalidation | Close below $510, then $496 | A decisive break below the $510 to $518 zone would weaken the swing uptrend. A break below $496 would require a deeper thesis review. |
MDGL AI trading strategy
The MDGL AI trading strategy is a rules-based framework for a high-growth, single-product specialty biopharma stock with competition and event risk. It is not personal advice and should be paired with live quotes, filings, position sizing, and MASH competitive checks.
Watch for MDGL to hold above the $510 to $518 support zone, stay above the rising SMA 50 and SMA 200 references, and work toward recent highs near $569 and the $615 area with confirming volume and no negative competitive or payer news.
A close below $510 should invalidate the short-term swing setup. A close below $496 should force a full review of Rezdiffra growth, competition, and cash runway assumptions.
If MDGL pulls back toward $510 to $518 or the SMA cluster without a new competitive, safety, or reimbursement problem, compare the price move with Q1 sales growth, patient trends, and cash of $817.9 million.
Do not treat every pullback as mean reversion. Specialty-pharma support levels can fail fast when competitor labels, net price cuts, or demand misses change the growth path.
Track Rezdiffra net sales, patient counts, U.S. and EU adoption, GLP-1 co-use and competition, gross-to-net trends, operating expenses, cash and debt, dilution, and pipeline programs including oral GLP-1 combination work.
Reduce confidence if valuation depends mainly on a premium sales multiple rather than durable patient growth, improving operating leverage, and a credible path to sustained free cash flow.
Investment research summary
Madrigal turns MASH diagnosis, specialist prescribing, and oral once-daily therapy into Rezdiffra product revenue for patients with metabolic dysfunction-associated steatohepatitis and fibrosis who previously had no approved disease-specific drug.
The moat is strongest where first-mover clinical data, labeling, specialist familiarity, manufacturing and supply execution, and EU expansion reinforce each other. It narrows if GLP-1 therapies or future MASH drugs match efficacy, convenience, access, or price.
The thesis fails if Rezdiffra demand slows, Novo Nordisk or other rivals take MASH share, payers cut net price, safety or label issues emerge, cash burn forces dilutive financing, or valuation multiples compress before profits arrive.
Management has converted a development-stage MASH story into a multi-hundred-million-dollar commercial franchise and is building pipeline depth, but capital allocation still must balance launch investment, combination programs, and shareholder dilution.
MASH sits inside a long-term rise in metabolic disease, underdiagnosis of liver fibrosis, and specialty-care treatment of obesity-related organ damage. GLP-1 adoption may expand diagnosis while also competing for the same patient pool.
MDGL is priced for continued high growth and eventual profitability after a strong launch. Margin of safety is limited if competition or reimbursement slows the path, but improves if patient growth stays elevated and operating losses shrink faster than expected.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| MDGL price | $536.70 | ChartMill technical close and Yahoo Finance quote cross-check | July 12, 2026 |
| Market capitalization | $12.38 billion, verified as $536.70 x 23.06 million shares | financial_rigor.py market cap verification and Yahoo Finance share count | July 12, 2026 |
| FY2025 Rezdiffra net sales | $958.4 million | Madrigal FY2025 earnings release and Macrotrends cross-check | July 12, 2026 |
| FY2025 net loss | $288.3 million | Madrigal FY2025 earnings release table | July 12, 2026 |
| Q1 2026 Rezdiffra net sales | $311.3 million, up 127% year over year | Madrigal Q1 2026 earnings release | July 12, 2026 |
| Q1 2026 net loss and EPS | About $94.4 million net loss and -$3.25 EPS | Madrigal Q1 2026 reporting summaries and earnings recaps | July 12, 2026 |
| Cash and marketable securities | $817.9 million as of March 31, 2026 | Madrigal Q1 2026 earnings release | July 12, 2026 |
| Rezdiffra patients at year-end 2025 | More than 36,250 patients on therapy | Madrigal FY2025 earnings release and Fierce Pharma coverage | July 12, 2026 |
| TTM revenue to March 31, 2026 | About $1.132 billion | Macrotrends MDGL revenue series | July 12, 2026 |
| Technical support and trend | Support $510.31 to $518.39, SMA 50 $511.48, SMA 200 $499.95, technical rating 10/10 | ChartMill technical analysis | July 12, 2026 |
This MDGL AI stock analysis page is an informational research tool only. It is not investment advice, a recommendation, or a guarantee of future performance. Forecast ranges are scenarios based on available data as of July 12, 2026 and can be wrong if financial results, competition, regulation, reimbursement, clinical data, interest rates, or market sentiment change.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
